Showing results (51-60 of 73) with videos related to
Sort By:
Pageof 8
Cell Death & Disease|March 3, 2022
Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathwayFeng Bai, Chuying Wang, Xiong Liu, et al.Journal of the American Medical Informatics Association : JAMIA|June 22, 2026
Benchmarking information extraction of physical activity from electronic health record with large language models: an natural language processing pipeline and comparative evaluationHan Yang, Zhongran Niu, Mingchen Li, et al.The Prostate|January 31, 2022
Protein signatures to distinguish aggressive from indolent prostate cancerFernando Garcia-Marques, Shiqin Liu, Sarah M Totten, et al.Breast Cancer Research : BCR|January 22, 2021
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumorsFeng Bai, Shiqin Liu, Xiong Liu, et al.Scientific Reports|June 26, 2021
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancerEn-Chi Hsu, Michelle Shen, Merve Aslan, et al.Scientific Reports|April 8, 2021
Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassayShiqin Liu, Fernando Garcia-Marques, Chiyuan Amy Zhang, et al.Proceedings of the National Academy of Sciences of the United States of America|November 14, 2023
Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategyNathanael J Bangayan, Liang Wang, Giselle Burton Sojo, et al.NPJ Breast Cancer|October 29, 2021
Oncogene-mediated metabolic gene signature predicts breast cancer outcomeMerve Aslan, En-Chi Hsu, Fernando J Garcia-Marques, et al.British Journal of Cancer|October 5, 2023
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotypeMichelle Shen, Shiqin Liu, Angus Toland, et al.British Journal of Cancer|December 8, 2020
Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancerShiqin Liu, Michelle Shen, En-Chi Hsu, et al.Pageof 8